肿瘤科指南

订阅

MedSci主页 / 所有栏目 / 肿瘤科指南

2020 ESMO临床实践指南：胃肠胰神经内分泌肿瘤的诊断，治疗和随访

2020-04-03 欧洲肿瘤内科学会 Ann Oncol. 2020 Apr 6.

胃肠胰神经内分泌肿瘤神经内分泌瘤

2020年4月，欧洲肿瘤内科学会(ESMO)发布了胃肠胰神经内分泌肿瘤的诊断，治疗和随访指南，神经内分泌肿瘤起源于弥漫性神经内分泌细胞系统，可发生在许多部位。本文主要针对胃肠胰神经内分泌肿瘤的诊断，治

中文标题：

2020 ESMO临床实践指南：胃肠胰神经内分泌肿瘤的诊断，治疗和随访

英文标题：

Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

发布机构：

欧洲肿瘤内科学会

发布日期：

2020-04-03

简要介绍：

2020年4月，欧洲肿瘤内科学会(ESMO)发布了胃肠胰神经内分泌肿瘤的诊断，治疗和随访指南，神经内分泌肿瘤起源于弥漫性神经内分泌细胞系统，可发生在许多部位。本文主要针对胃肠胰神经内分泌肿瘤的诊断，治疗和随访提出指导建议。

 

相关资料下载：
[AttachmentFileName(sort=1, fileName=)] GetToolGuiderByIdResponse(projectId=1, id=9edca1c0018926eb, title=2020 ESMO临床实践指南：胃肠胰神经内分泌肿瘤的诊断，治疗和随访, enTitle=Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up., guiderFrom=Ann Oncol. 2020 Apr 6., authorId=0, author=, summary=2020年4月，欧洲肿瘤内科学会(ESMO)发布了胃肠胰神经内分泌肿瘤的诊断，治疗和随访指南，神经内分泌肿瘤起源于弥漫性神经内分泌细胞系统，可发生在许多部位。本文主要针对胃肠胰神经内分泌肿瘤的诊断，治, cover=https://img.medsci.cn/2020419/1587306213296_2020535.jpg, journalId=0, articlesId=null, associationId=14, associationName=欧洲肿瘤内科学会, associationIntro=欧洲肿瘤内科学会（ESMO，European Society for Medical Oncology )是1975年成立的非盈利组织，是欧洲领先的专业组织，致力于提高肿瘤内科的专业性，推进癌症治疗和护理的多学科诊疗方法。, copyright=0, guiderPublishedTime=Fri Apr 03 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2020年4月，欧洲肿瘤内科学会(ESMO)发布了胃肠胰神经内分泌肿瘤的诊断，治疗和随访指南，神经内分泌肿瘤起源于弥漫性神经内分泌细胞系统，可发生在许多部位。本文主要针对胃肠胰神经内分泌肿瘤的诊断，治疗和随访提出指导建议。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=1095, tagName=胃肠胰神经内分泌肿瘤), TagDto(tagId=17316, tagName=神经内分泌瘤)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=76, categoryName=胃肠外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=91, categoryName=肝胆胰外科, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=17316, guiderKeyword=神经内分泌瘤, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3922, appHits=335, showAppHits=20, pcHits=1288, showPcHits=3618, likes=0, shares=17, comments=21, approvalStatus=1, publishedTime=Wed Apr 22 19:18:05 CST 2020, publishedTimeString=2020-04-03, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Sun Apr 19 22:23:40 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 22:06:24 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=)])
下载请点击：
评论区 (16)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1067586, encodeId=6ae5106e586c0, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=081f5687511, createdName=ms9000000892709945, createdTime=Sat Nov 06 14:41:10 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066355, encodeId=9d3b10663552b, content=学习学习，多参考, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=081f5687511, createdName=ms9000000892709945, createdTime=Tue Nov 02 20:34:43 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008706, encodeId=40841008e06f5, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff25575336, createdName=ms1000001256854968, createdTime=Tue Aug 17 14:32:22 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008681, encodeId=94fd1008681e4, content=棒棒棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff25575336, createdName=ms1000001256854968, createdTime=Tue Aug 17 13:59:05 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971259, encodeId=37cc9e125938, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd6c5514518, createdName=Leoliu123, createdTime=Sun Jun 06 10:19:52 CST 2021, time=2021-06-06, status=1, ipAttribution=)]
    2021-11-06 ms9000000892709945

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1067586, encodeId=6ae5106e586c0, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=081f5687511, createdName=ms9000000892709945, createdTime=Sat Nov 06 14:41:10 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066355, encodeId=9d3b10663552b, content=学习学习，多参考, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=081f5687511, createdName=ms9000000892709945, createdTime=Tue Nov 02 20:34:43 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008706, encodeId=40841008e06f5, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff25575336, createdName=ms1000001256854968, createdTime=Tue Aug 17 14:32:22 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008681, encodeId=94fd1008681e4, content=棒棒棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff25575336, createdName=ms1000001256854968, createdTime=Tue Aug 17 13:59:05 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971259, encodeId=37cc9e125938, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd6c5514518, createdName=Leoliu123, createdTime=Sun Jun 06 10:19:52 CST 2021, time=2021-06-06, status=1, ipAttribution=)]
    2021-11-02 ms9000000892709945

    学习学习，多参考

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1067586, encodeId=6ae5106e586c0, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=081f5687511, createdName=ms9000000892709945, createdTime=Sat Nov 06 14:41:10 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066355, encodeId=9d3b10663552b, content=学习学习，多参考, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=081f5687511, createdName=ms9000000892709945, createdTime=Tue Nov 02 20:34:43 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008706, encodeId=40841008e06f5, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff25575336, createdName=ms1000001256854968, createdTime=Tue Aug 17 14:32:22 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008681, encodeId=94fd1008681e4, content=棒棒棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff25575336, createdName=ms1000001256854968, createdTime=Tue Aug 17 13:59:05 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971259, encodeId=37cc9e125938, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd6c5514518, createdName=Leoliu123, createdTime=Sun Jun 06 10:19:52 CST 2021, time=2021-06-06, status=1, ipAttribution=)]
    2021-08-17 ms1000001256854968

    学习学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1067586, encodeId=6ae5106e586c0, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=081f5687511, createdName=ms9000000892709945, createdTime=Sat Nov 06 14:41:10 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066355, encodeId=9d3b10663552b, content=学习学习，多参考, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=081f5687511, createdName=ms9000000892709945, createdTime=Tue Nov 02 20:34:43 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008706, encodeId=40841008e06f5, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff25575336, createdName=ms1000001256854968, createdTime=Tue Aug 17 14:32:22 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008681, encodeId=94fd1008681e4, content=棒棒棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff25575336, createdName=ms1000001256854968, createdTime=Tue Aug 17 13:59:05 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971259, encodeId=37cc9e125938, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd6c5514518, createdName=Leoliu123, createdTime=Sun Jun 06 10:19:52 CST 2021, time=2021-06-06, status=1, ipAttribution=)]
    2021-08-17 ms1000001256854968

    棒棒棒

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1067586, encodeId=6ae5106e586c0, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=081f5687511, createdName=ms9000000892709945, createdTime=Sat Nov 06 14:41:10 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066355, encodeId=9d3b10663552b, content=学习学习，多参考, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=081f5687511, createdName=ms9000000892709945, createdTime=Tue Nov 02 20:34:43 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008706, encodeId=40841008e06f5, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff25575336, createdName=ms1000001256854968, createdTime=Tue Aug 17 14:32:22 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008681, encodeId=94fd1008681e4, content=棒棒棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff25575336, createdName=ms1000001256854968, createdTime=Tue Aug 17 13:59:05 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971259, encodeId=37cc9e125938, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd6c5514518, createdName=Leoliu123, createdTime=Sun Jun 06 10:19:52 CST 2021, time=2021-06-06, status=1, ipAttribution=)]
    2021-06-06 Leoliu123

    学习

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

肿瘤病理诊断规范胃肠胰神经内分泌肿瘤

中国肿瘤科相关专家小组（统称） · 2017-02-07

2016 中国胃肠胰神经内分泌肿瘤专家共识

CSCO 神经内分泌肿瘤专家委员会 · 2016-10-30

拓展阅读

2017 ENETS共识指南：小肠和胰腺神经内分泌瘤的手术治疗

欧洲神经内分泌肿瘤学会(ENETS,European Neuroendocrine Tumor Society) · 2017-02-28

2022 ESGE指南：包括神经内分泌瘤在内的上皮下病变的内镜治疗

欧洲胃肠道内窥镜学会(ESGE,European Society of Gastrointestinal Endoscopy) · 2022-02-18

澳大利亚共识声明：关于识别、预防和处理接受了肽受体放疗（PRRT）的神经内分泌肿瘤患者的激素危象

暂未更新 · 2022-09-01